HR and breast cancer: In the neoadjuvant setting, the combination of palbociclib plus letrozole was compared to chemotherapy in the Neopal Phase II trial with 106 patients with HR+/HER- node-positive, high-risk advanced luminal A/B breast cancer, as defined by the PAM50 gene panel.